Related Experiment Video
Updated: Aug 9, 2026
08:56
Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
Published on: April 7, 2023
Effects of third-generation aromatase inhibitors on bone
1Academic Unit of Bone Metabolism, Metabolic Bone Centre, Northern General Hospital, Sorby Wing, Herries Road, Sheffield S5 7AU, UK. e.v.mccloskey@shef.ac.uk
European Journal of Cancer (Oxford, England : 1990)
|March 24, 2006
Summary
Third-generation aromatase inhibitors (AIs) used for breast cancer treatment may affect bone turnover in postmenopausal women. Long-term effects on bone mineral density and fracture risk require further investigation.
Area of Science:
- Endocrinology
- Oncology
- Bone Metabolism
Background:
- Low estradiol levels are linked to reduced bone mineral density (BMD) and higher fracture risk.
- Third-generation aromatase inhibitors (AIs) significantly lower estrogen synthesis in postmenopausal women.
- AIs are crucial in breast cancer treatment but raise concerns about long-term bone health.
Purpose of the Study:
- To review current data on the effects of third-generation AIs on bone turnover markers, BMD, and fracture risk.
- To focus on findings related to adjuvant treatment of early breast cancer.
- To assess potential differences between steroidal and non-steroidal AIs regarding bone effects.
Main Methods:
- Review of available data on third-generation aromatase inhibitors (anastrozole, letrozole, exemestane).
- Emphasis on studies concerning adjuvant therapy for early breast cancer.
- Analysis of effects on bone turnover markers, BMD, and fracture incidence.
Main Results:
- Both steroidal (exemestane) and non-steroidal (anastrozole, letrozole) AIs appear to influence bone turnover.
- Clinical significance of potential differences between AI agents remains unclear.
- Further long-term data from ongoing adjuvant therapy studies are needed.
Conclusions:
- Third-generation AIs impact bone turnover, necessitating careful monitoring in postmenopausal breast cancer patients.
- Appropriate consideration of fracture risk and potential use of anti-osteoporotic therapies are essential.
- Long-term clinical data are required to fully elucidate the bone-related effects of these agents.
Related Concept Videos
01:29Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:17Hormones and Bone Tissue
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:40Bone Remodeling
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:31Osteoclasts in Bone Remodeling
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...